Notice of Proposed Sale · 144
Corcept Therapeutics Incorporated
CORTNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- CORCEPT THERAPEUTICS INC
- Issuer CIK
- 0001088856
- SEC file number
- 000-50679
- Phone
- 650.688.8803
- Person for whose account securities are to be sold
- Lyon Joseph Douglas
- Relationships to issuer
- Officer
- Street
- 101 REDWOOD SHORES PARKWAY
- City
- REDWOOD CITY
- State / country code
- CA
- Postal code
- 94065
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| common | 10,000 | 1,152,300.00 | 108,100,000 | 10/01/2026 | NASDAQ | Stifel Nicolaus |
Broker / market maker — proposed row 1, entry 1
- Name
- Stifel Nicolaus
- Street
- 501 N Broadway
- City
- St Louis
- State / country code
- MO
- Postal code
- 63102
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| common | 10/01/2026 | stock option exercise | Issuer | 10,000 | N | 10/01/2026 | cash |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| Joseph D Lyon | common | 08/03/2026 | 1,540 | 175,725.77 |
| Joseph D Lyon | common | 09/14/2026 | 10,000 | 1,134,423.74 |
Seller — prior-sale row 1, entry 1
- Name
- Joseph D Lyon
- Street
- 101 Redwood Shores Parkway
- City
- Redwood City
- State / country code
- CA
- Postal code
- 94065
Seller — prior-sale row 2, entry 1
- Name
- Joseph D Lyon
- Street
- 101 Redwood Shores Parkway
- City
- Redwood City
- State / country code
- CA
- Postal code
- 94065
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 10/01/2026
- Signed
- Joseph D Lyon
- Plan adoption dates
- 06/10/2026
Company context
For over 25 years, Corcept has focused on cortisol modulation and its potential to treat patients with a wide variety of serious disorders and has discovered more than 1,000 proprietary selective cortisol modulators and glucocorticoid receptor antagonists. Corcept is conducting advanced clinical trials in patients with hypercortisolism, solid tumors, ALS and liver disease.